Formulations of tegavivint and related compounds

1. A composition comprising:

a. 25 mg/ml of tegavivint or a pharmaceutically acceptable salt, ester, amide, stereoisomer or geometric isomer thereof;

b. 0.625% Poloxamer 188; and

c. 10% sorbitol;

wherein tegavivint or the pharmaceutically acceptable salt, ester, amide, stereoisomer or geometric isomer thereof is in the form of a nanosuspension comprising particles of tegavivint or the pharmaceutically acceptable salt, ester, amide, stereoisomer or geometric isomer thereof, and wherein the particles have an effective D50 of less than or equal to 500 nm and D90 of less than or equal to 1.0 micrometer (μm) when measured using laser diffraction, wherein the percentages are by weight of the composition.

2. The composition of claim 1 , wherein said composition is prepared by milling.

3. The composition of claim 1 , wherein said composition is prepared by LyoCell technology.

4. A process of preparing a composition comprising:

a) mixing particles of tegavivint

or a pharmaceutically acceptable salt, ester, amide, stereoisomer or geometric isomer thereof; with a Poloxamer 188 surfactant and an acceptable carrier to produce a suspension;

b) roller milling or using a high energy mill to mill the suspension of step (a); and

c) adding sorbitol to the particles of step (b)

to produce a formulation comprising 25 mg/ml of tegavivint or a pharmaceutically acceptable salt, ester, amide, stereoisomer or geometric isomer thereof; 0.625% Poloxamer 188; and 10% sorbitol;

wherein tegavivint or the pharmaceutically acceptable salt, ester, amide, stereoisomer or geometric isomer thereof is in the form of a nanosuspension comprising particles of tegavivint or the pharmaceutically acceptable salt, ester, amide, stereoisomer or geometric isomer thereof, and wherein the particles have an effective D50 of less than or equal to 500 nm and D90 of less than or equal to 1.0 micrometer (μm) when measured using laser diffraction, wherein the percentages are by weight of the composition.

5. The process of claim 4 , wherein the composition exhibits long term stability.

6. The composition of claim 1 , wherein the composition is formulated: (a) into a dosage form selected from the group consisting of tablets, and capsules; (b) into a dosage form selected from the group consisting of controlled release formulations, fast melt formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; (c) into a dosage form suitable for inhalation or parenteral administration; or (d) any combination of (a), (b), and (c).

7. A method of ameliorating cancer or tumor metastasis in a mammal in need thereof comprising administering to said mammal an effective amount of the composition of claim 1 .

8. A method for ameliorating cancer comprising administering to a subject in need thereof a combination of: 1) a pharmaceutically effective amount of the nanoparticulate composition of claim 1 ; and 2) a pharmaceutically effective amount of at least one additional anti-cancer agent.

9. The method of claim 8 , wherein the additional anti-cancer agent is selected from the group consisting of antimitotic agents, antimetabolite agents, HDAC inhibitors, proteosome inhibitors, immunotherapeutic agents, FLT-3 EGFR, MEK, PI3K and other protein kinase inhibitors, LSD1 inhibitors, and WNT pathway inhibitors, alkylating agents and DNA repair pathway inhibitors, anti-hormonal agents, anti-cancer antibodies, and other cytotoxic chemotherapy agents.

10. A method of alleviating, relieving or ameliorating a fibrotic disease in a mammal in need thereof comprising administering to said mammal an effective amount of the composition of claim 1 .

11. The method of claim 10 , wherein the fibrotic disease is selected from the group consisting of pulmonary fibrosis, Dupuytren's contracture, scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, keloids, chronic kidney disease, chronic graft rejection, and other scarring/wound healing abnormalities, post-operative adhesions, reactive fibrosis.